If you are:
FDB Contraindicated or Not Recommended: FDA C; ANIMAL DATA SUGGEST RISK IN 2ND AND 3RD TRIMESTER; INSUFF. HUMAN DATA
Precaution: EXCRETED IN RAT STUDIES;NOT RECOMMENDED BY MANUFACTURER.
An adult over 60:
management or monitoring precaution: Renal-Drug clearance may be affected by CrCL<50 mL/min. Particularly consider lower starting doses and slower dose titration with CrCL<30 mL/min to minimize hypotension, dizziness and falls. Endocrine-Beta-blocker may mask the symptoms of hypoglycemia and thus require more frequent monitoring in some patients with diabetes.
Giving bystolic to a child under 12:
management or monitoring precaution: No pediatric safety studies. Concerns of potential developmental toxicity.